0HF9 Stock Overview
A biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0HF9 from our risk checks.
Amicus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.57 |
| 52 Week High | US$14.57 |
| 52 Week Low | US$9.04 |
| Beta | 0.67 |
| 11 Month Change | -16.90% |
| 3 Month Change | -19.29% |
| 1 Year Change | -9.93% |
| 33 Year Change | -10.98% |
| 5 Year Change | n/a |
| Change since IPO | -40.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HF9 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.2% | -5.2% | 0.8% |
| 1Y | -9.9% | -20.1% | 6.6% |
Return vs Industry: 0HF9 exceeded the UK Biotechs industry which returned -20.1% over the past year.
Return vs Market: 0HF9 underperformed the UK Market which returned 6.6% over the past year.
Price Volatility
| 0HF9 volatility | |
|---|---|
| 0HF9 Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HF9 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0HF9's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 517 | Brad Campbell | amicusrx.com |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. Fundamentals Summary
| 0HF9 fundamental statistics | |
|---|---|
| Market cap | US$2.84b |
| Earnings (TTM) | -US$104.69m |
| Revenue (TTM) | US$493.67m |
5.8x
P/S Ratio-27.1x
P/E RatioIs 0HF9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HF9 income statement (TTM) | |
|---|---|
| Revenue | US$493.67m |
| Cost of Revenue | US$49.43m |
| Gross Profit | US$444.24m |
| Other Expenses | US$548.93m |
| Earnings | -US$104.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 89.99% |
| Net Profit Margin | -21.21% |
| Debt/Equity Ratio | 217.8% |
How did 0HF9 perform over the long term?
See historical performance and comparison